Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

40 results about "Bovine parainfluenza virus" patented technology

Bovine Respiratory Myxovirus Parainfluenza-3 This disease is caused by a virus from the paramyxovirus family and is known as the bovine parainfluenza virus type 3 (PI3). The disease is observed mostly in cattle. In the majority of cases, calves are said to be more susceptible to contracting the disease.

Recombined cattle parainfluenza carrier for expressing protein VP1 of porcine O type foot-and-mouth disease virus

The invention relates to a recombined cattle parainfluenza carrier pcDNA-NM09-VP1 for expressing the protein VP1 of a porcine O type foot-and-mouth disease virus. The recombined cattle parainfluenza carrier is characterized in that an RNA (ribonucleic acid) extracted from a strain BPIV3NM09 is used as a template; a virus total-length gene group is segmentally amplified through RT-PCR (reverse transcription-polymerase chain reaction); the total-length cDNA of cattle parainfluenza is subjected to primary modification, namely AgeI is introduced between P and M, so that insertion and replacement of exogenous antigen gene fragments are facilitated; due to secondary modification, antigen epitope which is inserted into a heterologous virus in a modified manner is the protein VP1 of the O type foot-and-mouth disease virus; the amino acid sequence is SEQIDNO1, and the nucleotide sequence is SEQIDNO2. The foundation is laid for further development of a gene engineering recombined vaccine for preventing and controlling the porcine foot-and-mouth disease and research on the III-type toxicity factor and the molecular pathogenesis of the cattle parainfluenza; the recombined cattle parainfluenza carrier has the replication capacity.
Owner:INST OF SPECIAL ANIMAL & PLANT SCI OF CAAS +1

Inactivation inspection method suitable for BVDV, IBRV, PIV3 and BRSV inactivated vaccines

InactiveCN108152498AGuaranteed infection timeImprove the detection rateMaterial analysisFreeze thawingAntigen
The invention discloses an inactivation inspection method suitable for BVDV, IBRV, PIV3 and BRSV inactivated vaccines, and relates to the field of biological medicines, in particular to an inactivation inspection method for BVDV, IBRV, PIV3 and BRSV inactivated vaccines. The inactivation inspection method comprises the following steps: (1) adsorbing an inactivated virus liquor on an appropriate cell for 40-60 min, and shaking for 2-3 times in the period; (2) after adsorption, adding a certain volume of a cell maintenance fluid in a cell spinner bottle, continuously performing culture, observing cytopathy, as for the virus fluid free from cytopathy, harvesting a cell culture fluid, and performing freeze thawing for 2-3 times; and (3) taking 10-15 ml of the frozen and thawed cell culture fluid, inoculating the taken cell culture fluid on the appropriate cell for adsorption, and continuously performing culture. Observation and fluorescence detection are performed, and if no specific fluorescence appears, complete inactivation is manifested. According to the technical scheme disclosed by the prevention, the anti-gen concentration and the virus infection time are guaranteed. The virus detection rate of the inactivation inspection method is high, and the bio-safety of the inactivated vaccines can be effectively ensured.
Owner:华威特(江苏)生物制药有限公司

Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines

Chimeric human-bovine parainfluenza viruses (PIVs) are infectious and attenuated in humans and other mammals and useful individually or in combination in vaccine formulations for eliciting an anti-PIV immune response. Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric PIV genome or antigenome which includes a partial or complete human or bovine PIV “background” genome or antigenome combined or integrated with one or more heterologous gene(s) or genome segment(s) of a different PIV. Chimeric human-bovine PIV of the invention include a partial or complete “background” PIV genome or antigenome derived from or patterned after a human or bovine PIV virus combined with one or more heterologous gene(s) or genome segment(s) of a different PIV virus to form the human-bovine chimeric PIV genome or antigenome. In certain aspects of the invention, chimeric PIV incorporate a partial or complete human PIV background genome or antigenome combined with one or more heterologous gene(s) or genome segment(s) from a bovine PIV, whereby the resultant chimeric virus is attenuated by virtue of host-range restriction. In alternate embodiments, human-bovine chimeric PIV incorporate a partial or complete bovine PIV background genome or antigenome combined with one or more heterologous gene(s) or genome segment(s) from a human PIV gene that encode a human PIV immunogenic protein, protein domain or epitope, for example encoded by PIV HN and/or F glycoprotein gene(s) or genome segment(s). Human-bovine chimeric PIV of the invention are also useful as vectors for developing vaccines against other pathogens. A variety of additional mutations and nucleotide modifications are provided within the human-bovine chimeric PIV of the invention to yield desired phenotypic and structural effects.
Owner:US DEPT OF HEALTH & HUMAN SERVICES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products